4,593 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC purchased a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the third quarter, Holdings Channel reports. The fund purchased 4,593 shares of the specialty pharmaceutical company’s stock, valued at approximately $605,000.

Several other large investors have also made changes to their positions in the business. Royal Bank of Canada raised its holdings in shares of Jazz Pharmaceuticals by 96.5% during the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after purchasing an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after purchasing an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after buying an additional 7,954 shares during the last quarter. Focus Partners Wealth raised its stake in shares of Jazz Pharmaceuticals by 3.4% during the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after buying an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $168.71 on Monday. The stock has a market capitalization of $10.25 billion, a P/E ratio of -27.79, a P/E/G ratio of 0.92 and a beta of 0.27. The company’s fifty day moving average price is $170.14 and its 200 day moving average price is $142.06. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $182.99.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several analyst reports. Wells Fargo & Company raised their target price on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Royal Bank Of Canada set a $194.00 price objective on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday, November 17th. Bank of America lifted their target price on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Morgan Stanley reissued an “overweight” rating and set a $225.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, January 8th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $188.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $205.67.

Insiders Place Their Bets

In other news, Director Bruce C. Cozadd sold 77,500 shares of the business’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the completion of the sale, the director owned 393,332 shares of the company’s stock, valued at $69,938,362.92. The trade was a 16.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Heather Ann Mcsharry sold 3,415 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $177.78, for a total transaction of $607,118.70. Following the completion of the transaction, the director directly owned 20,449 shares in the company, valued at $3,635,423.22. This represents a 14.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 123,791 shares of company stock valued at $21,991,850. 4.30% of the stock is owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.